Bayesian Capital Management, LP Allogene Therapeutics, Inc. Transaction History

Bayesian Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $78,946 - $155,060	35,402 New	35,402 $82,000
Q3 2023 Nov 14, 2023	BUY	$3.17 - $5.96 $39,308 - $73,904	12,400 Added 87.94%	26,500 $84,000
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $63,873 - $95,034	14,100 New	14,100 $70,000
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $206,112 - $373,312	-30,400 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $232,560 - $464,816	30,400 New	30,400 $277,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.